Built on the largest unified Indian pharmaceutical layer.
Every brand, every generic, every salt canonicalised across regulators and retailer catalogues. The numbers below update at every build — no stale screenshots.
Beyond the retail catalogue.
The four categories of pharmaceutical intelligence India needs and most sources don't carry. Cross-cutting, structured, queryable.
Clinical-grade monographs
Class B monographs with bias audits, regulatory context, and India-specific positioning. The boring-but-critical caveats retail catalogues skip.
Pharmacogenomic recommendations
CPIC / DPWG / FDA Level-A recommendations cross-linked at the molecule level. Surface CYP2C19 / HLA-B*15:02 / TPMT signals before you write.
Adverse-event signal layer
FAERS / EMA / CDSCO disproportionality scores, boxed warnings, Dear-Doctor letters, severity-tiered. Real signals, not headline anecdotes.
Salt-canonical resolution
One molecule, hundreds of brands. The data layer canonicalises at the salt level — your queries don't hop through 50 spelling variants.
See the data your prescription deserves.
Each DrugIQ drug page bundles composition, salt-canonical lineage, regulator status, brand alternatives, pricing telemetry, pharmacogenomic recommendations, and adverse-event signals. One page, one source of truth.
- Composition + dosage form + strength
- Salt-anchored brand alternatives
- Pharmacogenomic alerts (CPIC Level A first)
- Adverse-event severity & disproportionality
- Pricing across channels, time-series
- Source attribution for every claim
Three pieces. One coherent product.
Ingest authoritative sources
PubChem, ChEMBL, RxNorm, CPIC, FDA SPL, EMA EPAR, CDSCO, NLEM, NPPA. Plus Indian retailer signals. Continuous refresh on a 90/180-day cycle for safety-critical fields.
Canonicalise at the salt level
Salt-canonical anchoring deduplicates 578K brands down to 1.7K molecules. Cross-walks across regulators happen at the molecule level, never at the brand level.
Surface the clinical layer
Pharmacogenomic recommendations, adverse-event signals, regulatory facts, alternative-drug graphs — exposed via API and a queryable data product, not buried in PDFs.
People who need answers, not headlines.
Clinicians
PGx alerts at the point of prescribing. Real adverse-event severity, not anecdotes.
Pharmacists
Substitution checks, dispense-side verification, salt-canonical lookups.
Researchers
Structured access to a deduplicated pharmaceutical layer with source attribution.
Pharma industry
Competitive intelligence, regulatory comparators, brand-level pricing telemetry.
Every claim has a source. Every monograph has a review.
Class B clinical monographs follow a 22-section playbook with an explicit bias audit. Safety-critical fields refresh every 60 days. Pricing telemetry refreshes weekly. The full operating contract is public.
Read the playbookClass B monograph review
22-section structure with bias audit, retailer-leak scan, regulatory-context anchor.
Source attribution per field
Each clinical fact carries an attribution row — source, retrieval date, reviewer, decay clock.
Trust tiers
Three explicit tiers: unverified (catalog-only), AI-reviewed (cross-checked), pharmacist-reviewed (signed off).
Refresh cadence
Safety-critical: 60d. Other: 180d. Pricing: weekly. Last refresh shown on every page.
DrugIQ is in private preview.
We're onboarding clinicians, pharmacists, and research teams in waves. Tell us about how you'd use DrugIQ and we'll get back within a working week.